help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on November 8, 2007
Endocrinology, doi:10.1210/en.2007-1220
A more recent version of this article appeared on February 1, 2008
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
149/2/476    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xu, Q.
Right arrow Articles by Du, X.-J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xu, Q.
Right arrow Articles by Du, X.-J.

Submitted on September 4, 2007
Accepted on October 26, 2007

Endogenous Relaxin Does Not Affect Chronic Pressure Overload-Induced Cardiac Hypertrophy and Fibrosis

Qi Xu, Edna D. Lekgabe, Xiao-Ming Gao, Ziqiu Ming, Geoffrey W. Tregear, Anthony M. Dart, Ross A.D. Bathgate, Chrishan S. Samuel, and Xiao-Jun Du*

Baker Heart Research Institute, and Howard Florey Institute, University of Melbourne, Melbourne, Australia

* To whom correspondence should be addressed. E-mail: xiaojun.du{at}baker.edu.au.

The effect of endogenous relaxin on the development of cardiac hypertrophy, dysfunction and fibrosis remains completely unknown. We addressed this question by subjecting relaxin-1 deficient (Rln1-/-) and littermate control (Rln1+/+) mice of both genders to chronic transverse aortic constriction (TAC). The extent of left ventricular (LV) remodeling and dysfunction were studied by serial echocardiography over an 8-week period and by micromanometry. The degree of hypertrophy was estimated by LV weight, cardiomyocyte size and expression of relevant genes. Cardiac fibrosis was determined by hydroxyproline assay and quantitative histology. Expression of endogenous relaxin during the course of TAC was also examined. In response to an 8-week period of pressure overload, TAC mice of both genotypes developed significant LV hypertrophy, fibrosis, hypertrophy-related gene profile, and signs indicating congestive heart failure when compared to respective sham controls. The severity of these alterations was not statistically different between the two genotypes of either gender. Relaxin mRNA expression was up-regulated, while that of its receptor was unchanged in the hypertrophic myocardium of wild-type mice. Collectively, the extent of pressure overload-induced LV hypertrophy, fibrosis and dysfunction were comparable between Rln1+/+ and Rln1-/- mice. Thus, although up-regulated in its expression, endogenous relaxin had no significant effect on the progression of cardiac maladaptation and dysfunction in the setting of chronic pressure overload.


Key words: extracellular matrix • cardiac fibrosis • hypertrophy • relaxin • ventricular function







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2007 by The Endocrine Society